589 bytes added
, 11:30, 14 July 2016
{{Startups
|website=http://fannininnovation.com/portfolio/acelerox/
|accelerator=Fannin Innovation Studio
}}
ACELEROX is developing novel antioxidant nanoparticles that serve as therapies for reactive oxygen species (ROS)-mediated disease. ROS has been implicated in the progression of a broad range of diseases, including rheumatoid arthritis, multiple sclerosis, ischemic stroke and traumatic brain injury. The companys proprietary class of molecules, termed PEG-HCCs, can be used to directly treat the symptoms of these diseases as well as to deliver chemotherapeutic drugs into tumors.